Down-regulation of tumor necrosis factor-α, moderate reduction of interleukin-1β, but not interleukin-6 or interleukin-10, by glucan immunomodulators curdlan sulfate and lentinan

The effects of glucan-based immunomodulators curdlan sulfate (CRDS) and lentinan on cytokine production stimulated by lipopolysaccharide (LPS) in bacillus Calmette-Guerin (BCG)-primed mice were investigated. Pretreatment with CRDS or lentinan before LPS administration induced a striking inhibition o...

Full description

Saved in:
Bibliographic Details
Published in:International journal of immunopharmacology 1997-09, Vol.19 (9), p.463-468
Main Authors: Noel Masihi, K., Madaj, Katja, Hintelmann, Henny, Gast, Gerd, Kaneko, Yutaro
Format: Article
Language:English
Subjects:
BCG
Biological and medical sciences
curdlan sulfate
Escherichia coli
glucan
immunomodulator
Immunomodulators
interleukin-1
interleukin-10
interleukin-6
lentinan
Medical sciences
Pharmacology. Drug treatments
tumor necrosis factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c367t-759e12db6c0d56b81008e6b8c98b4736ab75646966922e20ecc29be697b18db63
cites cdi_FETCH-LOGICAL-c367t-759e12db6c0d56b81008e6b8c98b4736ab75646966922e20ecc29be697b18db63
container_end_page 468
container_issue 9
container_start_page 463
container_title International journal of immunopharmacology
container_volume 19
creator Noel Masihi, K.
Madaj, Katja
Hintelmann, Henny
Gast, Gerd
Kaneko, Yutaro
description The effects of glucan-based immunomodulators curdlan sulfate (CRDS) and lentinan on cytokine production stimulated by lipopolysaccharide (LPS) in bacillus Calmette-Guerin (BCG)-primed mice were investigated. Pretreatment with CRDS or lentinan before LPS administration induced a striking inhibition of up to 89% of circulating tumor necrosis factor-α (TNF), a moderate reduction of 25% of interleukin (IL)-lβ, no significant differences in IL-6 or IL-10 levels, and a marked depression of chemiluminescence activity. Animals receiving CRDS prior to infection with α-hemolysin positive Escherichia coli inhibited measurable TNF production by 63%. The ability of CRDS and lentinan to significantly reduce the TNF production in vivo indicates the potential of glucans in possible therapeutic strategies that are based on down-regulation of TNF.
doi_str_mv 10.1016/S0192-0561(97)00056-8
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_16460240</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0192056197000568</els_id><sourcerecordid>16460240</sourcerecordid><originalsourceid>FETCH-LOGICAL-c367t-759e12db6c0d56b81008e6b8c98b4736ab75646966922e20ecc29be697b18db63</originalsourceid><addsrcrecordid>eNqFkd1qFjEQhoMo-Fm9BCEHIgqNJtndZHMkpf5CwQP1OGSzsyWaTWp-lF6WpdfRazLbrxZ65NEE5nnfmcmL0FNGXzHKxOsvlClO6CDYCyVfUtpeZLyHdmyUinS9Gu6j3S3yED3K-fsGMcF36PJt_B1IgtPqTXEx4LjgUteYcACbYnYZL8aWmMjVn0O8xhmSKYATzNX-410okDzUHy4QdnVxiKdacIjlTkPg5nmHpA08x6e-WhOwW9caYvPf9ogpY1vT7FsjV79sE02YsYdQXDDhMXqwGJ_hyU09QN_ev_t6_JGcfP7w6fjohNhOyELkoIDxeRKWzoOYRkbpCK1aNU697ISZ5CB6oYRQnAOnYC1XEwglJzY2WXeAnu99z1L8WSEXvbpswbe9INasWVNT3tMGDntw-7KcYNFnya0mnWtG9ZaRvs5IbwFoJfV1Rnpsumc3A0y2xi_JBOvyrZh3A-2pbNibPQbt2F8Oks7WQbAwuwS26Dm6_wz6C7VRqsE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16460240</pqid></control><display><type>article</type><title>Down-regulation of tumor necrosis factor-α, moderate reduction of interleukin-1β, but not interleukin-6 or interleukin-10, by glucan immunomodulators curdlan sulfate and lentinan</title><source>ScienceDirect Freedom Collection</source><creator>Noel Masihi, K. ; Madaj, Katja ; Hintelmann, Henny ; Gast, Gerd ; Kaneko, Yutaro</creator><contributor>Masihi, KN</contributor><creatorcontrib>Noel Masihi, K. ; Madaj, Katja ; Hintelmann, Henny ; Gast, Gerd ; Kaneko, Yutaro ; Masihi, KN</creatorcontrib><description>The effects of glucan-based immunomodulators curdlan sulfate (CRDS) and lentinan on cytokine production stimulated by lipopolysaccharide (LPS) in bacillus Calmette-Guerin (BCG)-primed mice were investigated. Pretreatment with CRDS or lentinan before LPS administration induced a striking inhibition of up to 89% of circulating tumor necrosis factor-α (TNF), a moderate reduction of 25% of interleukin (IL)-lβ, no significant differences in IL-6 or IL-10 levels, and a marked depression of chemiluminescence activity. Animals receiving CRDS prior to infection with α-hemolysin positive Escherichia coli inhibited measurable TNF production by 63%. The ability of CRDS and lentinan to significantly reduce the TNF production in vivo indicates the potential of glucans in possible therapeutic strategies that are based on down-regulation of TNF.</description><identifier>ISSN: 0192-0561</identifier><identifier>EISSN: 1879-3495</identifier><identifier>DOI: 10.1016/S0192-0561(97)00056-8</identifier><identifier>CODEN: IJIMDS</identifier><language>eng</language><publisher>Oxford: Elsevier Science</publisher><subject>BCG ; Biological and medical sciences ; curdlan sulfate ; Escherichia coli ; glucan ; immunomodulator ; Immunomodulators ; interleukin-1 ; interleukin-10 ; interleukin-6 ; lentinan ; Medical sciences ; Pharmacology. Drug treatments ; tumor necrosis factor</subject><ispartof>International journal of immunopharmacology, 1997-09, Vol.19 (9), p.463-468</ispartof><rights>1998</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c367t-759e12db6c0d56b81008e6b8c98b4736ab75646966922e20ecc29be697b18db63</citedby><cites>FETCH-LOGICAL-c367t-759e12db6c0d56b81008e6b8c98b4736ab75646966922e20ecc29be697b18db63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,23930,23931,25140,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2350407$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><contributor>Masihi, KN</contributor><creatorcontrib>Noel Masihi, K.</creatorcontrib><creatorcontrib>Madaj, Katja</creatorcontrib><creatorcontrib>Hintelmann, Henny</creatorcontrib><creatorcontrib>Gast, Gerd</creatorcontrib><creatorcontrib>Kaneko, Yutaro</creatorcontrib><title>Down-regulation of tumor necrosis factor-α, moderate reduction of interleukin-1β, but not interleukin-6 or interleukin-10, by glucan immunomodulators curdlan sulfate and lentinan</title><title>International journal of immunopharmacology</title><description>The effects of glucan-based immunomodulators curdlan sulfate (CRDS) and lentinan on cytokine production stimulated by lipopolysaccharide (LPS) in bacillus Calmette-Guerin (BCG)-primed mice were investigated. Pretreatment with CRDS or lentinan before LPS administration induced a striking inhibition of up to 89% of circulating tumor necrosis factor-α (TNF), a moderate reduction of 25% of interleukin (IL)-lβ, no significant differences in IL-6 or IL-10 levels, and a marked depression of chemiluminescence activity. Animals receiving CRDS prior to infection with α-hemolysin positive Escherichia coli inhibited measurable TNF production by 63%. The ability of CRDS and lentinan to significantly reduce the TNF production in vivo indicates the potential of glucans in possible therapeutic strategies that are based on down-regulation of TNF.</description><subject>BCG</subject><subject>Biological and medical sciences</subject><subject>curdlan sulfate</subject><subject>Escherichia coli</subject><subject>glucan</subject><subject>immunomodulator</subject><subject>Immunomodulators</subject><subject>interleukin-1</subject><subject>interleukin-10</subject><subject>interleukin-6</subject><subject>lentinan</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>tumor necrosis factor</subject><issn>0192-0561</issn><issn>1879-3495</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><recordid>eNqFkd1qFjEQhoMo-Fm9BCEHIgqNJtndZHMkpf5CwQP1OGSzsyWaTWp-lF6WpdfRazLbrxZ65NEE5nnfmcmL0FNGXzHKxOsvlClO6CDYCyVfUtpeZLyHdmyUinS9Gu6j3S3yED3K-fsGMcF36PJt_B1IgtPqTXEx4LjgUteYcACbYnYZL8aWmMjVn0O8xhmSKYATzNX-410okDzUHy4QdnVxiKdacIjlTkPg5nmHpA08x6e-WhOwW9caYvPf9ogpY1vT7FsjV79sE02YsYdQXDDhMXqwGJ_hyU09QN_ev_t6_JGcfP7w6fjohNhOyELkoIDxeRKWzoOYRkbpCK1aNU697ISZ5CB6oYRQnAOnYC1XEwglJzY2WXeAnu99z1L8WSEXvbpswbe9INasWVNT3tMGDntw-7KcYNFnya0mnWtG9ZaRvs5IbwFoJfV1Rnpsumc3A0y2xi_JBOvyrZh3A-2pbNibPQbt2F8Oks7WQbAwuwS26Dm6_wz6C7VRqsE</recordid><startdate>19970901</startdate><enddate>19970901</enddate><creator>Noel Masihi, K.</creator><creator>Madaj, Katja</creator><creator>Hintelmann, Henny</creator><creator>Gast, Gerd</creator><creator>Kaneko, Yutaro</creator><general>Elsevier Science</general><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>19970901</creationdate><title>Down-regulation of tumor necrosis factor-α, moderate reduction of interleukin-1β, but not interleukin-6 or interleukin-10, by glucan immunomodulators curdlan sulfate and lentinan</title><author>Noel Masihi, K. ; Madaj, Katja ; Hintelmann, Henny ; Gast, Gerd ; Kaneko, Yutaro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c367t-759e12db6c0d56b81008e6b8c98b4736ab75646966922e20ecc29be697b18db63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>BCG</topic><topic>Biological and medical sciences</topic><topic>curdlan sulfate</topic><topic>Escherichia coli</topic><topic>glucan</topic><topic>immunomodulator</topic><topic>Immunomodulators</topic><topic>interleukin-1</topic><topic>interleukin-10</topic><topic>interleukin-6</topic><topic>lentinan</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>tumor necrosis factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Noel Masihi, K.</creatorcontrib><creatorcontrib>Madaj, Katja</creatorcontrib><creatorcontrib>Hintelmann, Henny</creatorcontrib><creatorcontrib>Gast, Gerd</creatorcontrib><creatorcontrib>Kaneko, Yutaro</creatorcontrib><collection>Pascal-Francis</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>International journal of immunopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Noel Masihi, K.</au><au>Madaj, Katja</au><au>Hintelmann, Henny</au><au>Gast, Gerd</au><au>Kaneko, Yutaro</au><au>Masihi, KN</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Down-regulation of tumor necrosis factor-α, moderate reduction of interleukin-1β, but not interleukin-6 or interleukin-10, by glucan immunomodulators curdlan sulfate and lentinan</atitle><jtitle>International journal of immunopharmacology</jtitle><date>1997-09-01</date><risdate>1997</risdate><volume>19</volume><issue>9</issue><spage>463</spage><epage>468</epage><pages>463-468</pages><issn>0192-0561</issn><eissn>1879-3495</eissn><coden>IJIMDS</coden><abstract>The effects of glucan-based immunomodulators curdlan sulfate (CRDS) and lentinan on cytokine production stimulated by lipopolysaccharide (LPS) in bacillus Calmette-Guerin (BCG)-primed mice were investigated. Pretreatment with CRDS or lentinan before LPS administration induced a striking inhibition of up to 89% of circulating tumor necrosis factor-α (TNF), a moderate reduction of 25% of interleukin (IL)-lβ, no significant differences in IL-6 or IL-10 levels, and a marked depression of chemiluminescence activity. Animals receiving CRDS prior to infection with α-hemolysin positive Escherichia coli inhibited measurable TNF production by 63%. The ability of CRDS and lentinan to significantly reduce the TNF production in vivo indicates the potential of glucans in possible therapeutic strategies that are based on down-regulation of TNF.</abstract><cop>Oxford</cop><pub>Elsevier Science</pub><doi>10.1016/S0192-0561(97)00056-8</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0192-0561
ispartof International journal of immunopharmacology, 1997-09, Vol.19 (9), p.463-468
issn 0192-0561
1879-3495
language eng
recordid cdi_proquest_miscellaneous_16460240
source ScienceDirect Freedom Collection
subjects BCG
Biological and medical sciences
curdlan sulfate
Escherichia coli
glucan
immunomodulator
Immunomodulators
interleukin-1
interleukin-10
interleukin-6
lentinan
Medical sciences
Pharmacology. Drug treatments
tumor necrosis factor
title Down-regulation of tumor necrosis factor-α, moderate reduction of interleukin-1β, but not interleukin-6 or interleukin-10, by glucan immunomodulators curdlan sulfate and lentinan
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T08%3A23%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Down-regulation%20of%20tumor%20necrosis%20factor-%CE%B1,%20moderate%20reduction%20of%20interleukin-1%CE%B2,%20but%20not%20interleukin-6%20or%20interleukin-10,%20by%20glucan%20immunomodulators%20curdlan%20sulfate%20and%20lentinan&rft.jtitle=International%20journal%20of%20immunopharmacology&rft.au=Noel%20Masihi,%20K.&rft.date=1997-09-01&rft.volume=19&rft.issue=9&rft.spage=463&rft.epage=468&rft.pages=463-468&rft.issn=0192-0561&rft.eissn=1879-3495&rft.coden=IJIMDS&rft_id=info:doi/10.1016/S0192-0561(97)00056-8&rft_dat=%3Cproquest_cross%3E16460240%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c367t-759e12db6c0d56b81008e6b8c98b4736ab75646966922e20ecc29be697b18db63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=16460240&rft_id=info:pmid/&rfr_iscdi=true